Home » Stocks » SLP

Simulations Plus, Inc. (SLP)

Stock Price: $56.00 USD 0.58 (1.05%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.12B
Revenue (ttm) 41.59M
Net Income (ttm) 9.33M
Shares Out 19.93M
EPS (ttm) 0.50
PE Ratio 112.00
Forward PE 98.04
Dividend $0.24
Dividend Yield 0.43%

Stock Quote

Trading Day November 27
Last Price $56.00
Previous Close $55.42
Change ($) 0.58
Change (%) 1.05%
Day's Open 55.31
Day's Range 54.69 - 56.48
Day's Volume 78,873
52-Week Range 26.00 - 77.89

More Stats

Market Cap 1.12B
Enterprise Value 1.00B
Earnings Date (est) n/a
Ex-Dividend Date Oct 23, 2020
Shares Outstanding 19.93M
Float n/a
EPS (basic) 0.52
EPS (diluted) 0.50
FCF / Share 0.47
Dividend $0.24
Dividend Yield 0.43%
Earnings Yield 0.89%
FCF Yield 0.75%
Payout Ratio 46.20%
Shares Short 1.17M
Short Ratio 7.45
Short % of Float n/a
Beta 0.01
PE Ratio 112.00
Forward PE 98.04
P/FCF Ratio 134.04
PS Ratio 26.84
PB Ratio 7.08
Revenue 41.59M
Operating Income 11.61M
Net Income 9.33M
Free Cash Flow 8.33M
Net Cash 115.08M
Net Cash / Share 5.77
Gross Margin 74.39%
Operating Margin 27.90%
Profit Margin 22.40%
FCF Margin 20.02%
ROA 7.62%
ROE 9.64%
ROIC 44.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 3
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(47.77% upside)
Current: $56.00
Target: 82.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth22.43%14.51%22.9%20.86%9.05%59.8%13.8%6.58%8.12%-
Gross Profit30.9424.9421.6717.8315.3713.929.838.427.947.18
Operating Income11.6110.6510.308.267.235.864.444.073.613.53
Net Income9.338.588.935.794.953.843.032.893.032.71
Shares Outstanding17.8217.4917.3317.2417.0316.8616.1716.0015.7615.54
Earnings Per Share0.500.480.500.330.
EPS Growth4.17%-4%51.52%13.79%26.09%27.78%0%-5.26%11.76%-
Dividend Per Share0.
Dividend Growth0%0%20%0%0%5.26%-24%66.67%--
Operating Cash Flow10.9111.649.296.885.427.145.312.563.783.50
Capital Expenditures-2.58-1.96-2.33-1.56-1.23-1.24-3.89-1.18-1.07-0.82
Free Cash Flow8.339.686.965.324.185.901.411.382.722.68
Cash & Equivalents11611.449.406.228.038.558.6110.1812.7010.18
Total Debt0.93---------
Net Cash / Debt11511.449.406.228.038.558.6110.1812.7010.18
Book Value15637.6831.9225.8022.7319.5315.4414.2415.1414.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Simulations Plus, Inc.
Country United States
Employees 129
CEO Shawn M. O'Connor

Stock Information

Ticker Symbol SLP
Stock Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Unique Identifier NASDAQ: SLP
IPO Date June 18, 1997


Simulations Plus develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.